TABLE 1.
Five AEs most frequently discussed in papers describing chloroquine (CQ) use in various disease states (as discerned by a search of EMBASE).
| COVID-19 | Systematic Lupus Erythematosus (SLE) | Malaria | |||
|---|---|---|---|---|---|
| Adverse Event | Frequency (% a ) | Adverse Event | Frequency (% a ) | Adverse Event | Frequency (% a ) |
| QT Prolongation | 38 (43.7%) | Retinopathy | 8 (34.8%) | General Side Effects | 8 (32%) |
| Heart Arrhythmia | 13 (14.9%) | Cardiomyopathy | 6 (26.1%) | Headache | 7 (28%) |
| Torsade des Pointes | 13 (14.9%) | Eye Toxicity | 5 (21.7%) | Retinopathy | 7 (28%) |
| Retinopathy | 11 (12.6%) | Heart Arrhythmia | 4 (17.4%) | QT Prolongation | 6 (24%) |
| General Side Effects | 9 (10.3%) | Diarrhea | 3 (13.0%) | Nausea | 5 (20%) |
a
Percentage of papers reporting this AE, as classified by the EMBASE database.